↓ Skip to main content

Cochrane Database of Systematic Reviews

Cardioselective beta-blockers for reversible airway disease

Overview of attention for article published in Cochrane database of systematic reviews, October 2002
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

blogs
1 blog
twitter
3 X users
wikipedia
17 Wikipedia pages
video
1 YouTube creator

Readers on

mendeley
198 Mendeley
citeulike
1 CiteULike
Title
Cardioselective beta-blockers for reversible airway disease
Published in
Cochrane database of systematic reviews, October 2002
DOI 10.1002/14651858.cd002992
Pubmed ID
Authors

Shelley R Salpeter, Thomas M Ormiston, Edwin E Salpeter, Richard Wood-Baker

Abstract

Beta-blocker therapy has mortality benefit in patients with hypertension, heart failure and coronary artery disease, as well as during the perioperative period. These drugs have traditionally been considered contraindicated in patients with reversible airway disease. To assess the effect of cardioselective beta-blockers in patients with asthma or COPD. A search of EMBASE, MEDLINE and CINAHL was performed up to May 2002 using the terms: asthma*, bronchial hyperreactivity*, respiratory sounds*, wheez*, obstructive lung disease* or obstructive airway disease*, and adrenergic antagonist*, sympatholytic* or adrenergic receptor block*. Randomized, blinded, placebo-controlled trials of single dose or continued treatment of the effects of cardioselective beta-blockers in patients with reversible airway disease. Two independent reviewers extracted data from the selected articles, reconciling differences by consensus. Beta1-blockers were divided into those with or without intrinsic sympathomimetic activity (ISA). Interventions were: administration of single or continued beta1-blocker, and response to beta2-agonist given after the study drug. Nineteen studies on single-dose treatment and 10 studies on continued treatment met the inclusion criteria. Single dose cardioselective beta-blocker produced a 7.46% (95% CI 5.59, 9.32) reduction in FEV1, but with a 4.63% (95% CI 2.47, 6.78) increase in FEV1 with beta2-agonist, compared to placebo. Treatment lasting 3 - 28 days produced no change in FEV1 (-0.42%; 95% CI -3.74, 2.91), symptoms or inhaler use, whilst maintaining a 8.74% (95% CI 1.96, 15.52) response to beta2-agonist. There was no significant change in FEV1 treatment effect for those patients with COPD: single doses -5.28% (95% CI -10.03, -0.54%), continued treatment 1.07% (CI -3.3, 5.44. With continued treatment there was no significant difference in FEV1 response for beta1-blockers without ISA compared to those with IS: -3.22% (96%CI -7.79, 1.36) compared to 2.72% (95% CI -2.12, 7.59). Those without ISA produced a 12.0% increase in FEV1 after beta2-agonist administration compared to placebo (95%CI 4.12,19.87) while beta1-blockers with ISA produced no change compared to placebo (-0.60% [95%CI -13.93, 12.73). These results were obtained in a small number od studies of few patients. The difference was not significant. Cardioselective beta-blockers given in mild - moderate reversible airway disease or COPD, do not produce adverse respiratory effects in the short term. Given their demonstrated benefit in conditions such as heart failure, cardiac arrhythmias and hypertension, these agents should not be withheld from such patients, but long term safety (especially their impact during an acute exacerbation) still needs to be established.

Timeline
X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 198 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 <1%
France 1 <1%
United Kingdom 1 <1%
New Zealand 1 <1%
Egypt 1 <1%
Japan 1 <1%
United States 1 <1%
Unknown 191 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 26 13%
Researcher 22 11%
Student > Bachelor 17 9%
Student > Ph. D. Student 16 8%
Other 11 6%
Other 33 17%
Unknown 73 37%
Readers by discipline Count As %
Medicine and Dentistry 65 33%
Nursing and Health Professions 16 8%
Pharmacology, Toxicology and Pharmaceutical Science 12 6%
Social Sciences 6 3%
Agricultural and Biological Sciences 5 3%
Other 16 8%
Unknown 78 39%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 August 2024.
All research outputs
#2,705,654
of 25,728,855 outputs
Outputs from Cochrane database of systematic reviews
#5,350
of 13,136 outputs
Outputs of similar age
#3,146
of 51,047 outputs
Outputs of similar age from Cochrane database of systematic reviews
#3
of 25 outputs
Altmetric has tracked 25,728,855 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,136 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.8. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 51,047 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.